“
TL;DR
There was no significant difference in hemorrhagic complications between the groups, supporting the safety of continuing DOACs through cataract surgery.
International Ophthalmology · 4 authors, 6 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
There was no significant difference in hemorrhagic complications between the groups, supporting the safety of continuing DOACs through cataract surgery.
No thromboembolic events occurred in either group. The study is limited by its retrospective design, relatively small sample size, and lack of comparison between continuing and withholding DOACs. The findings support that uninterrupted DOAC therapy during phacoemulsification is feasible and safe, though larger studies are needed.